According to filings with the U.S. Securities and Exchange Commission, Anodyne Nanotech has raised $12,600,000.00 in new Series A funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Velocity Partners VC, Evercurious VC, and Relativity Healthcare Partners.

About Anodyne Nanotech
Anodyne Nanotech is a biotechnology company, developing next-generation transdermal therapeutics. The company’s solid-state microneedle technology is designed to deliver multi-milligram doses of large molecules (peptides, antibodies, and nucleic acid therapeutics) through a convenient, room-temperature-stable patch, while maintaining injection-level efficacy. Anodyne’s lead program, ANN-101, is a once-weekly GLP-1 patch for obesity. The company is headquartered in Boston, Massachusetts.

To learn more, visit https://www.theheropatch.com/
Linkedin: https://www.linkedin.com/company/hero-patch/

Contact:
Jake Lombardo, Chief Executive Officer
https://www.linkedin.com/in/jake-lombardo/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.